RachelMHuckfeldtMDPhD

Ophthalmology • Boston, MA

Retinal Disease

Assistant Professor, Ophthalmology, Harvard Medical School

Join to view full profile

Dr. Huckfeldt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Huckfeldt's full profile

Already have an account?

Office
Massachusetts Eye and Ear Infirmary
243 Charles Street
Boston, MA 02114
Phone+1 617-573-3621

Education & Training

Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolResidency, Ophthalmology, 2010 - 2013
Washington University in St. Louis School of MedicineClass of 2009, MD, PhD
University of Iowa Hospitals and ClinicsFellowship, Medical Retina
Newton-Wellesley HospitalInternship, Transitional Year
University of PennsylvaniaPostdoctoral Research, Ophthalmology
Massachusetts Eye and EarFellowship, Inherited Retinal Degenerations

Certifications & Licensure

MA State Medical License 2015 - 2025
IA State Medical License 2014 - 2016
PA State Medical License 2013 - 2014
American Board of Ophthalmology Ophthalmology

Clinical Trials

Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial) Start of enrollment: 2017 Aug 03
Active, not recruiting
Phase 1, Phase 2
Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene Start of enrollment: 2020 Dec 04
Active, not recruiting
Phase 3

Publications & Presentations

PubMed

A novel homozygous nonsense variant incausing stationary cone/rod synaptic dysfunction.
Blake M Hauser, Emily Place, Rachel Huckfeldt, Demetrios G Vavvas
Ophthalmic Genetics. 2024-12-01
Coding and non-coding variants in the ciliopathy gene CFAP410 cause early-onset non-syndromic retinal degeneration.
Riccardo Sangermano, Priya Gupta, Cherrell Price, Jinu Han, Julien Navarro
NPJ Genomic Medicine. 2024-11-08
Phase 1/2 AAV5-hRKp.RPGR (Botaretigene Sparoparvovec) Gene Therapy: Safety and Efficacy in RPGR-Associated X-Linked Retinitis Pigmentosa.
Michel Michaelides, Cagri G Besirli, Yesa Yang, Thales A C DE Guimaraes, Sui Chien Wong
American Journal of Ophthalmology. 2024-11-01

Press Mentions

AGTC Reports 12-Month Data from Its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 GeneJune 24th, 2021
Foundation Fighting Blindness to Jointly Host Online Continuing Medical Education (CME, COPE) WebinarSeptember 24th, 2020
Mass General Research Awards and Honors: October 2018November 15th, 2018
Join now to see all